메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 26, Issue 29, 2008, Pages 4848-4849
SWOG S0023: What meets the eye may be only half the truth
Author keywords

[No Author keywords available]
Indexed keywords

GEFITINIB; K RAS PROTEIN; PLACEBO;
EID: 54249153414     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.4218     Document Type: Letter
Times cited : (4)
References (8)
  • 1
    • 45149102984 scopus 로고    scopus 로고
    • Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
    • Kelly K, Chansky K, Gaspar LE, et al: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 2450-2456
    • Kelly, K.1    Chansky, K.2    Gaspar, L.E.3
  • 2
    • 84871468507 scopus 로고    scopus 로고
    • A pilot study of sequential therapy with gefitinib following chemotherapy in advanced non-small cell lung cancer (NSCLC)
    • suppl 2
    • Bhutani M, Pathak AK, Guleria R, et al: A pilot study of sequential therapy with gefitinib following chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 49:S236-S237, 2005 (suppl 2)
    • (2005) Lung Cancer , vol.49
    • Bhutani, M.1    Pathak, A.K.2    Guleria, R.3
  • 3
    • 45149099893 scopus 로고    scopus 로고
    • Does gefitinib shorten lung cancer survival? Chaos redux
    • Keedy VL, Arteaga CL, Johnson DH: Does gefitinib shorten lung cancer survival? Chaos redux. J Clin Oncol 26:2428-2430, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 2428-2430
    • Keedy, V.L.1    Arteaga, C.L.2    Johnson, D.H.3
  • 4
    • 0037093249 scopus 로고    scopus 로고
    • Influence of unrecognized molecular heterogeneity on randomized clinical trials
    • Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495-2499, 2002
    • (2002) J Clin Oncol , vol.20 , pp. 2495-2499
    • Betensky, R.A.1    Louis, D.N.2    Cairncross, J.G.3
  • 5
    • 39849097128 scopus 로고    scopus 로고
    • Epidermal growth factor receptor inhibitors in the treatment of lung cancer: Reality and hopes
    • Wheatley-Price P, Shepherd FA: Epidermal growth factor receptor inhibitors in the treatment of lung cancer: Reality and hopes. Curr Opin Oncol 20:162-175, 2008
    • (2008) Curr Opin Oncol , vol.20 , pp. 162-175
    • Wheatley-Price, P.1    Shepherd, F.A.2
  • 6
    • 45149084723 scopus 로고    scopus 로고
    • First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    • Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442-2449, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 2442-2449
    • Sequist, L.V.1    Martins, R.G.2    Spigel, D.3
  • 7
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3
  • 8
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
    • (2005) Lancet , vol.366 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.